Immunocore stock gets a fresh 3.6 percent ownership filing

Immunocore stock (ISIN US45258D1054) was last at USD 29.41 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, down 0.47 percent from the prior close. The fresh ownership filing gives investors a new data point as the biotechnology company advances its melanoma pipeline.

FMR filing shows 3.6 percent stake

As StockTitan reported on October 7, 2026, FMR LLC disclosed beneficial ownership of 1,736,979 Immunocore common shares, equal to 3.6 percent of the class. The filing listed sole voting power over 1,732,649 shares and sole dispositive power over 1,736,979 shares.

The filing identifies September 30, 2026 as the event date and describes the position as an ordinary-course holding. Its neutral ownership character makes the disclosure more relevant as a governance data point than as a direct operating catalyst.

KIMMTRAK sales rose 18 percent

In the Q2 2026 earnings call, Benzinga reported that KIMMTRAK sales reached USD 116 million, up 18 percent from Q2 2025. First-half 2026 net revenue reached USD 223 million, a 16 percent increase from the first half of 2025.

The call also disclosed USD 880 million in cash and marketable securities as of June 30, 2026. Management said a USD 6 million US distributor inventory stocking event supported Q2 sales, creating a defined comparison point for the underlying commercial trend.

Consensus target remains above Nasdaq price

Paasa lists a Buy consensus based on 9 buy ratings, 5 hold ratings and 0 sell ratings. The published median target is USD 39.00, with a USD 35.00 low and USD 43.00 high, putting the median 32.6 percent above the October 7 price.

IMCR stock stays below its yearly high

IMCR was last at USD 29.41 on Nasdaq on October 7, 2026, with a session range of USD 29.15 to USD 29.82. The 52-week range was USD 27.55 to USD 40.72, while market capitalization stood at USD 1.5 billion and volume reached 343,751 shares.

More news and analyses on Immunocore stock